Last reviewed · How we verify
NCT03887026
Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis
Phase 2 trial testing Norketotifen in Allergic Rhinitis in 36 participants. Completed in 29 May 2019.
18 May 2019
Quick facts
| Lead sponsor | Emergo Therapeutics, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 1 April 2019 |
| Primary completion | 18 May 2019 |
| Estimated completion | 29 May 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Norketotifen — full drug profile →
- Placebo
Conditions studied
- Allergic Rhinitis — all drugs for Allergic Rhinitis →
- Allergic Rhinoconjunctivitis — all drugs for Allergic Rhinoconjunctivitis →
Sponsor
Emergo Therapeutics, Inc. — full company profile →
Who can join
Adults 18 to 45, any sex, with Allergic Rhinitis or Allergic Rhinoconjunctivitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase 2a study to evaluate the efficacy and safety of Norketotifen (NKT) in subjects with allergic rhinitis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03887026
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Norketotifen
Trials testing the same drug.
- NCT04610047 — Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness · Phase 2 · completed
- NCT04043923 — Norketotifen for the Treatment of Uncomplicated Influenza-like Illness · Phase 2 · completed
Other recruiting trials for Allergic Rhinitis
Currently open trials in the same condition.
- NCT07453615 — Effect of AI(Artificial Intelligence)-Based Storytelling Video on Anxiety and Fear During Skin Prick Test in Children · NA · recruiting
- NCT07419230 — Evaluation of a Digital Tool to Improve Aeroallergen Immunotherapy Adherence. NavigAITme Project · NA · recruiting
- NCT06960382 — Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Ast · Phase 1, PHASE2 · recruiting
- NCT07455968 — Free Diving Breathing Training in Allergic Rhinitis · NA · active not recruiting
- NCT07115342 — Effect of Combined Probiotics and Vitamin D on Symptoms of Allergic Rhinitis · NA · recruiting
Other Emergo Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT04610047 — Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness · Phase 2 · completed
- NCT04043923 — Norketotifen for the Treatment of Uncomplicated Influenza-like Illness · Phase 2 · completed
- NCT03712163 — Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Norketotifen in Healthy Subjects · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03887026 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Emergo Therapeutics, Inc.
- Last refreshed: 21 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03887026.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing